A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus

Inclusion Criteria: * Diagnosis of SLE with positive ANA * Stable disease with no change in SLE therapy within the previous 30 days * BMI from 18 to 38 kg/m2 Exclusion Criteria: * Have had signs or symptoms of a viral, bacterial or fungal infection within 30 days of study randomization * Evidence of renal disease or liver disease * Any history of granulomatous disease including autoimmune granulomatous vasculitis and sarcoidosis * Prior administration of any other biologic that primarily targets the immune system